John D. Schreier

发表

Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs

Christopher I. Bayly, Georgia B. McGaughey, Richard Ball, 2014, Journal of Computer-Aided Molecular Design.

Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.

John D. Schreier, I. Raheem, J. Fuerst, 2016, Bioorganic & medicinal chemistry letters.

Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.

Steven V. Fox, John D. Schreier, J. Renger, 2014, Bioorganic & medicinal chemistry letters.

Discovery of [(2R,5R)‐5‐{[(5‐Fluoropyridin‐2‐yl)oxy]methyl}‐2‐methylpiperidin‐1‐yl][5‐methyl‐2‐(pyrimidin‐2‐yl)phenyl]methanone (MK‐6096): A Dual Orexin Receptor Antagonist with Potent Sleep‐Promoting Properties

Steven V. Fox, John D. Schreier, S. Doran, 2012, ChemMedChem.

Kinesin spindle protein (KSP) inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP.

John D. Schreier, Youwei Yan, P. Coleman, 2007, Bioorganic & medicinal chemistry letters.

Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat.

John D. Schreier, S. Doran, G. McGaughey, 2010, Bioorganic & medicinal chemistry letters.

Discovery of a Potent, CNS‐Penetrant Orexin Receptor Antagonist Based on an N,N‐Disubstituted‐1,4‐diazepane Scaffold that Promotes Sleep in Rats

John D. Schreier, S. Doran, J. Renger, 2009, ChemMedChem.

Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.

John D. Schreier, I. Raheem, J. Fuerst, 2012, Bioorganic & medicinal chemistry letters.

C-O cross-coupling of activated aryl and heteroaryl halides with aliphatic alcohols.

John D. Schreier, I. Raheem, S. Krska, 2012, Angewandte Chemie.

Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.

John D. Schreier, S. Doran, G. McGaughey, 2010, Journal of medicinal chemistry.

Discovery of 5′′‐Chloro‐N‐[(5,6‐dimethoxypyridin‐2‐yl)methyl]‐2,2′:5′,3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia

Steven V. Fox, John D. Schreier, J. Renger, 2014, ChemMedChem.

Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.

John D. Schreier, Min Xu, D. Hazuda, 2015, Journal of medicinal chemistry.

Pharmacological characterization of MK-6096 – A dual orexin receptor antagonist for insomnia

Steven V. Fox, John D. Schreier, S. Doran, 2012, Neuropharmacology.

Efficient synthesis of highly functionalized tetrahydropyridopyrimidines by a novel three-component coupling reaction

John D. Schreier, I. Raheem, M. Breslin, 2011 .

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey

Dawn M. Toolan, John D. Schreier, I. Raheem, 2013, Neuropharmacology.

Discovery and optimization of 2-pyridinone aminal integrase strand transfer inhibitors for the treatment of HIV.

John D. Schreier, Min Xu, D. Hazuda, 2017, Bioorganic & medicinal chemistry letters.

Correction to Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.

John D. Schreier, Min Xu, D. Hazuda, 2016, Journal of Medicinal Chemistry.

Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.

John D. Schreier, I. Raheem, J. Fuerst, 2012, Bioorganic & medicinal chemistry letters.